Suppr超能文献

免疫调节剂苯丁抑制素在哺乳动物细胞表面结合位点的特性及特异性

Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells.

作者信息

Müller W E, Schuster D K, Zahn R K, Maidhof A, Leyhausen G, Falke D, Koren R, Umezawa H

出版信息

Int J Immunopharmacol. 1982;4(5):393-400. doi: 10.1016/0192-0561(82)90012-1.

Abstract

The binding of the immunomodulator bestatin, an inhibitor of cell surface bound leucine aminopeptidase and aminopeptidase B, to mammalian cells of varying origin has been studied. The specific binding of [3H] bestatin was a rapid and saturable process exhibiting one affinity, characterized by an association constant of 0.8 x 10(5) M-1, as determined in the L5178y mouse lymphoma system. Optimal binding was observed at 37 degrees C. L-leucine and L-leucine-beta-naphthylamide prevented the binding, suggesting that the complex was formed between leucine aminopeptidase and bestatin. The protein nature of the bestatin-"receptor" was suggested by its susceptibility to trypsin. Under the conditions used here intracellular translocation of bestatin appeared to be negligible. A maximum of about 2.2 x 10(6) bestatin molecules could bind to L5178y mouse lymphoma cells. Under identical conditions by far the highest amount of bestatin was bound to macrophages from mice. Lower levels were measured with T-lymphocytes; very low binding capacity was observed with B-lymphocytes. Experiments with synchronized L5178y cells revealed a cell cycle dependent change of binding capacity for bestatin; the highest level was observed during the transition from S-to G2 phase and the lowest during G1- and early S phase. These data lend further support to the assumption that the immuno-potentiating activity of bestatin is due to a stimulation of T-lymphocyte proliferation probably mediated through the activation of macrophages.

摘要

已对免疫调节剂贝他定(一种细胞表面结合型亮氨酸氨肽酶和氨肽酶B的抑制剂)与不同来源的哺乳动物细胞的结合进行了研究。在L5178y小鼠淋巴瘤系统中测定,[3H]贝他定的特异性结合是一个快速且可饱和的过程,表现出一种亲和力,其缔合常数为0.8×10⁵ M⁻¹。在37℃观察到最佳结合。L-亮氨酸和L-亮氨酸-β-萘酰胺可阻止结合,这表明亮氨酸氨肽酶与贝他定之间形成了复合物。贝他定“受体”的蛋白质性质可由其对胰蛋白酶的敏感性表明。在此处使用的条件下,贝他定的细胞内转运似乎可以忽略不计。最多约2.2×10⁶个贝他定分子可与L5178y小鼠淋巴瘤细胞结合。在相同条件下,到目前为止,贝他定与小鼠巨噬细胞的结合量最高。T淋巴细胞的结合水平较低;B淋巴细胞的结合能力非常低。对同步化的L5178y细胞进行的实验揭示了贝他定结合能力的细胞周期依赖性变化;在从S期到G2期的转变过程中观察到最高水平,而在G1期和早期S期观察到最低水平。这些数据进一步支持了以下假设,即贝他定的免疫增强活性是由于可能通过巨噬细胞的激活介导的T淋巴细胞增殖的刺激。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验